Schwab provided guidance for Q3 2025, expecting revenues of $190 million to $193 million and adjusted EBITDA of $38 million to $40 million. For the full year, the company now expects revenues of $750 ...
Total revenues of $666.8 million for the full year 2024, representing a 16.5% year-over-year increase, indicating strong business growth. Cloud revenues grew by 28.6% year-over-year for the full year ...
On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from ...
Vertex Pharmaceuticals (VRTX) is expected to report its Q4 and full year 2024 results on February 10th of 2024. The expectations are that its earnings are going to decline, but it revenues are still ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results